WO2006076100A3 - Tubulin isotype screening in cancer therapy using halichondrin b analogs - Google Patents

Tubulin isotype screening in cancer therapy using halichondrin b analogs Download PDF

Info

Publication number
WO2006076100A3
WO2006076100A3 PCT/US2005/044421 US2005044421W WO2006076100A3 WO 2006076100 A3 WO2006076100 A3 WO 2006076100A3 US 2005044421 W US2005044421 W US 2005044421W WO 2006076100 A3 WO2006076100 A3 WO 2006076100A3
Authority
WO
WIPO (PCT)
Prior art keywords
halichondrin
analogs
correlations
microtubule
cancer
Prior art date
Application number
PCT/US2005/044421
Other languages
French (fr)
Other versions
WO2006076100A2 (en
Inventor
Sergei Agoulnik
Galina Kuznetsov
Bruce A Littlefield
Original Assignee
Eisai Co Ltd
Sergei Agoulnik
Galina Kuznetsov
Bruce A Littlefield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd, Sergei Agoulnik, Galina Kuznetsov, Bruce A Littlefield filed Critical Eisai Co Ltd
Priority to EP05857058A priority Critical patent/EP1831697A4/en
Priority to JP2007545622A priority patent/JP2008522623A/en
Publication of WO2006076100A2 publication Critical patent/WO2006076100A2/en
Publication of WO2006076100A3 publication Critical patent/WO2006076100A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Chemotherapeutic agents that interfere with microtubule assembly or disassembly in the cell are potent inhibitors of cell replication. Examples of such agents include halichondrin B analogs. It has been shown that the susceptibility of certain cancers to analogs of halichondrin B correlates with the expression of particular tubulin isotypes or other microtubule-associated proteins such as MAP-4 and stathmin. Correlations such as these may be used in identifying patients suitable for treatment using a particular chemotherapeutic agent. Such a system avoids treating patients with cytotoxic compounds where there is a minimal or no effect on the cancer. The invention also provides a system of establishing these correlations for different compounds and cancer types. The system will be particularly useful in establishing correlations between anti-microtubule agents and cancers such as lung, breast, and ovarian cancer. Kits and reagents useful in practicing the invention are also provided.
PCT/US2005/044421 2004-12-09 2005-12-07 Tubulin isotype screening in cancer therapy using halichondrin b analogs WO2006076100A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05857058A EP1831697A4 (en) 2004-12-09 2005-12-07 Tubulin isotype screening in cancer therapy using halichondrin b analogs
JP2007545622A JP2008522623A (en) 2004-12-09 2005-12-07 Screening for tubulin isotypes in cancer treatment using halichondrin B analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63473404P 2004-12-09 2004-12-09
US60/634,734 2004-12-09

Publications (2)

Publication Number Publication Date
WO2006076100A2 WO2006076100A2 (en) 2006-07-20
WO2006076100A3 true WO2006076100A3 (en) 2009-04-02

Family

ID=36678067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044421 WO2006076100A2 (en) 2004-12-09 2005-12-07 Tubulin isotype screening in cancer therapy using halichondrin b analogs

Country Status (5)

Country Link
US (2) US20060154312A1 (en)
EP (1) EP1831697A4 (en)
JP (1) JP2008522623A (en)
TW (1) TW200634309A (en)
WO (1) WO2006076100A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
PL2522663T3 (en) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Intermediates for the preparation of halichondrin B
MX2010003599A (en) 2007-10-03 2010-09-10 Eisai R&D Man Co Ltd Intermediates and methods for the synthesis of halichondrin b analogs.
CN105801599A (en) * 2008-04-04 2016-07-27 卫材R&D管理有限公司 Halichondrin b analogs
WO2010145693A1 (en) * 2009-06-16 2010-12-23 Università Cattolica del Sacro Cuore Predictive evaluation of the response to taxane-including chemotherapy
BR112012018232B8 (en) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd FURO [3,2-B] PYRAN DERIVATIVE COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICONDRIN B ANALOGS AND ER-80402 AND ERIBULIN SYNTHESIS METHODS
KR101947529B1 (en) 2010-05-31 2019-02-13 런던 헬스 사이언시스 센터 리서치 인코포레이티드 RHAMM Binding Peptides
HUE032625T2 (en) * 2011-01-21 2017-10-30 Basilea Pharmaceutica Ag Use of stathmin as a biomarker of drug response to furazanobenzimidazoles
EP2686441B1 (en) * 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
CA2929084C (en) 2013-11-04 2022-01-11 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin b
GB201320061D0 (en) * 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
EP3077399B1 (en) 2013-12-06 2019-02-20 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs
EP3160970A4 (en) 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthesis of halichondrin analogs and uses thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
MX2017014237A (en) 2015-05-07 2018-09-17 Eisai R&D Man Co Ltd Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides.
RU2732575C2 (en) 2016-02-12 2020-09-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Intermediate products in synthesis of eribulin and corresponding methods of synthesis
AU2017225982B2 (en) 2016-03-02 2023-10-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
KR102404629B1 (en) 2016-06-30 2022-06-02 에자이 알앤드디 매니지먼트 가부시키가이샤 Prince Reaction and Intermediates Useful for Synthesis of Halicondine Macrolides and Analogs thereof
JP6978758B2 (en) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ Palladium-mediated ketolization
SG11201908603PA (en) 2017-04-05 2019-10-30 Harvard College Macrocyclic compound and uses thereof
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US11548898B2 (en) 2017-07-06 2023-01-10 President And Fellows Of Harvard College Synthesis of halichondrins
IT201700117860A1 (en) * 2017-10-18 2019-04-18 Molipharma Srl TEST AND KIT FOR DIAGNOSIS OF OVARIAN CARCINOMA
CN111328328B (en) * 2017-11-09 2023-05-23 研成精密化学株式会社 Intermediate for preparing eribulin mesylate and preparation method thereof
EP3710454B1 (en) 2017-11-15 2024-01-03 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
SG11202005548WA (en) 2018-01-03 2020-07-29 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065894A1 (en) * 1998-06-17 1999-12-23 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP2008522624A (en) * 2004-12-09 2008-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 Screening for tubulin isotypes in cancer therapy using hemiasterlin analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065894A1 (en) * 1998-06-17 1999-12-23 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AGOULNIK ET AL: "Journal of Clinical Oncology, 2005 ACSO Annual Meeting Proceedings.", vol. 23, 1 June 2005, pages: 16, XP008119836 *
BAI ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 24, 1991, pages 15882 - 15889, XP008119781 *
BLUM ET AL: "Journal of Clinical Oncology. 2006 ASCO Annual Meeting Proceedings Part 1.", vol. 24, 20 June 2006, pages: 18 *
KAVALLARIS M ET AL, CANCER RESEARCH, vol. 61, 2001, pages 5803 - 5809, XP008119782 *
KUZNETSOV G ET AL., CANCER RESEARCH, vol. 64, no. 16, 2004, pages 5760 - 5766, XP009128436 *

Also Published As

Publication number Publication date
EP1831697A4 (en) 2011-01-26
WO2006076100A2 (en) 2006-07-20
US20060154312A1 (en) 2006-07-13
TW200634309A (en) 2006-10-01
US20100190843A1 (en) 2010-07-29
JP2008522623A (en) 2008-07-03
EP1831697A2 (en) 2007-09-12

Similar Documents

Publication Publication Date Title
WO2006076100A3 (en) Tubulin isotype screening in cancer therapy using halichondrin b analogs
WO2006063135A3 (en) Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
TW200626174A (en) Biomarkers for pre-selection of patients for anti-IGF1R therapy
WO2006044826A3 (en) Thiophens and their use as anti-tumor agents
TW200508214A (en) Novel compounds
EP1622616A4 (en) Inhibitors of akt activity
TW200635599A (en) Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
HK1091731A1 (en) Pharmaceutical use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
MX2007004276A (en) 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity.
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
IL180722A0 (en) Thienopyrimidine derivatives and pharmaceutical compositions containing the same
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MX2007011545A (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors.
WO2003106416A3 (en) Chemical process
WO2003080582A3 (en) Fredericamycin derivatives
BRPI0512974A (en) New Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases
WO2003087831A3 (en) Proteins involved in breast cancer
GB2430935A (en) Tetrapeptide analogs
NO20055832L (en) Preparation and use of arylalkyl acid derivatives for the treatment of obesity
WO2006067465A3 (en) Cancer treatment
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
MX2010007948A (en) Iap inhibitors.
WO2006029020A3 (en) Treatments of refractory cancers using na+/k+-atpase inhibitors
WO2004032882A3 (en) Chemical compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007545622

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005857058

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005857058

Country of ref document: EP